Revisiting sensitivity of senescent cells to BH3 mimetics

IF 13.9 1区医学 Q1 PHARMACOLOGY & PHARMACY

Trends in pharmacological sciences Pub Date : 2024-01-20 DOI:10.1016/j.tips.2024.01.002

Nadine Martin, Anda Huna, Athanasios Tsalikis, David Bernard

引用次数: 0

Abstract

B cell leukemia/lymphoma 2 (BCL2) homology domain 3 (BH3) mimetics were reported to selectively kill senescent cells and improve age-related diseases. Defining why these cells show increased sensitivity to these molecules will help to identify new pharmacological compounds with senolytic activity. Here, we discuss how recent research findings provide new clues to understand this vulnerability.

查看原文本刊更多论文

重新审视衰老细胞对 BH3 模拟物的敏感性

据报道，B细胞白血病/淋巴瘤2（BCL2）同源结构域3（BH3）模拟物可选择性地杀死衰老细胞并改善与年龄有关的疾病。明确为什么这些细胞对这些分子表现出更高的敏感性将有助于确定具有衰老活性的新药理化合物。在此，我们将讨论最近的研究成果如何为了解这种脆弱性提供了新的线索。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Trends in pharmacological sciences 医学-药学

CiteScore

23.90

自引率

0.70%

发文量

132

审稿时长

6-12 weeks

期刊介绍： Trends in Pharmacological Sciences (TIPS) is a monthly peer-reviewed reviews journal that focuses on a wide range of topics in pharmacology, pharmacy, pharmaceutics, and toxicology. Launched in 1979, TIPS publishes concise articles discussing the latest advancements in pharmacology and therapeutics research. The journal encourages submissions that align with its core themes while also being open to articles on the biopharma regulatory landscape, science policy and regulation, and bioethics. Each issue of TIPS provides a platform for experts to share their insights and perspectives on the most exciting developments in the field. Through rigorous peer review, the journal ensures the quality and reliability of published articles. Authors are invited to contribute articles that contribute to the understanding of pharmacology and its applications in various domains. Whether it's exploring innovative drug therapies or discussing the ethical considerations of pharmaceutical research, TIPS provides a valuable resource for researchers, practitioners, and policymakers in the pharmacological sciences.